TAKE Solutions Limited (IN:TAKE)
:TAKE
Top Page
TAKE Solutions Limited
(TAKE)
Select Model
Select Model
Rating:50Neutral
Price Target:
₹36.00
▼(-11.15% Downside)
Action:N/ADate:01/04/26
The score is held down primarily by weak financial performance (zero FY2025 revenue, operating losses, and volatile/weak recent cash flow), despite some balance-sheet improvement in FY2025. Technicals are supportive due to a strong uptrend, but overbought signals reduce confidence. Valuation is moderate based on the P/E, with no dividend data to add support.
Positive Factors
Life‑sciences software & services focus
TAKE’s core business is a niche technology and services play for regulated life‑sciences firms, a structural market with ongoing demand for compliance, clinical and regulatory IT. This specialization supports durable demand for software and consulting as regulatory complexity and digitalization persist.
Negative Factors
Revenue collapsed to zero (FY2025)
Reporting zero revenue in FY2025 is a fundamental durability concern: it erodes recurring contract bases, undermines pricing power and scale economics, and makes recovery reliant on rebuilding top‑line demand rather than marginal cost or efficiency moves alone.
Read all positive and negative factors
Positive Factors
Negative Factors
Life‑sciences software & services focus
TAKE’s core business is a niche technology and services play for regulated life‑sciences firms, a structural market with ongoing demand for compliance, clinical and regulatory IT. This specialization supports durable demand for software and consulting as regulatory complexity and digitalization persist.
Read all positive factors
TAKE Solutions Limited (TAKE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹6.47B
Dividend YieldN/A
Average Volume (3M)58.94K
Price to Earnings (P/E)131.6
Beta (1Y)1.32
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees203
SectorServices
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)0.08
Shares Outstanding147,934,000
10 Day Avg. Volume129,011
30 Day Avg. Volume58,943
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)5.00
Price to Sales (P/S)0.00
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TAKE Solutions Limited Business Overview & Revenue Model
Company Description
TAKE Solutions Limited, together with its subsidiaries, provides domain-intensive services and solutions in life sciences and supply chain management in the United States, the Asia Pacific, and Europe. The company offers IP-driven and technology b...
How the Company Makes Money
null...
TAKE Solutions Limited Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
48
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 85.23M | 0.00 | 656.08M | 1.89B | 6.53B | 7.74B |
| Gross Profit | -250.00K | -450.00K | 411.67M | 1.06B | 4.60B | 5.86B |
| EBITDA | 49.91M | 27.44M | -1.05B | -209.79M | 269.00M | -2.86B |
| Net Income | 481.77M | 374.67M | -1.20B | -1.00B | -7.82B | -4.52B |
Balance Sheet | ||||||
| Total Assets | 352.13M | 364.79M | 881.05M | 2.24B | 12.23B | 18.45B |
| Cash, Cash Equivalents and Short-Term Investments | 1.50M | 156.91M | 8.49M | 113.36M | 290.71M | 390.45M |
| Total Debt | 0.00 | 0.00 | 370.85M | 463.69M | 779.90M | 5.50B |
| Total Liabilities | 95.84M | 159.52M | 969.78M | 1.16B | 10.42B | 7.20B |
| Stockholders Equity | 256.29M | 205.27M | -88.73M | 1.09B | 1.81B | 11.25B |
Cash Flow | ||||||
| Free Cash Flow | -31.39M | -163.66M | 14.00M | -123.81M | 890.99M | 1.32B |
| Operating Cash Flow | -31.39M | -163.66M | 93.16M | 200.15M | 1.20B | 1.35B |
| Investing Cash Flow | 270.00K | 220.20M | -74.62M | -21.25M | -306.41M | -569.89M |
| Financing Cash Flow | -130.00K | -32.39M | -117.35M | -357.21M | -545.17M | -839.46M |
TAKE Solutions Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹1.13B | -15.68 | ― | ― | 28.58% | 68.42% | |
58 Neutral | ₹1.20B | 33.72 | ― | 0.51% | -0.22% | -51.08% | |
56 Neutral | ₹694.18M | -0.73 | ― | 0.42% | -9.83% | -5.90% | |
55 Neutral | $13.29B | 17.42 | 10.03% | 0.93% | 7.13% | -12.93% | |
50 Neutral | ₹6.47B | 131.64 | ― | ― | ― | ― |
* Services Sector Average
IN:TAKE
TAKE Solutions Limited
43.72
35.47
429.94%
IN:BSL
BSL Ltd
117.05
-49.06
-29.53%
IN:DHRUV
Dhruv Consultancy Services Ltd.
36.60
-35.14
-48.98%
IN:ODIGMA
Odigma Consultancy Solutions Limited
26.08
-15.92
-37.90%
IN:SECMARK
SecMark Consultancy Ltd.
108.45
23.87
28.22%
IN:SEMAC
Semac Consultants Ltd
274.10
-45.70
-14.29%
TAKE Solutions Limited Corporate Events
TAKE Solutions Names New Statutory Auditor After Resignation
Mar 26, 2026
TAKE Solutions Limited has announced that its board of directors, acting on the audit committee’s recommendation, has approved the appointment of M/s A. Raghavendra Rao Associates as the company’s statutory auditors to fill a casual v...
TAKE Solutions appoints new statutory auditor after resignation of previous firm
Mar 26, 2026
TAKE Solutions Limited has announced a change in its statutory auditors following the resignation of its previous audit firm, Venkat and Rangaa LLP, Chartered Accountants. Based on the Audit Committee’s recommendation, the Board has approved...
TAKE Solutions Unveils AI-Driven Take.Health Platform for India’s Preventive Healthcare Market
Mar 25, 2026
TAKE Solutions Limited has launched Take.Health, an AI-driven digital health companion designed to turn lifestyle and medical data into personalized health intelligence for India’s growing online population. Positioned at the intersection of...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.